Search

Displaying results 2701 - 2710 of 5419 in total
  1. Drug

    MEM 1414

    go.drugbank.com/drugs/DB05888
    Experimental

    MEM 1414 works by blocking phosphodiesterase, an enzyme that breaks down an important brain chemical, cyclic AMP. It appears to work in the area of the brain where new memories are formed.

  2. Drug

    Zinc citrate

    go.drugbank.com/drugs/DB11154
    ApprovedInvestigational

    Zinc citrate is a zinc salt of citric acid. It is available as dietary supplements as a treatment of zinc deficiency and source of zinc, which is an essential trace element. Zinc citrate demonstrates effective absorption following oral a...

    Categories: Agents for Treatment of Hemorrhoids and Anal Fissures for Topical Use
  3. Drug

    Rusfertide

    go.drugbank.com/drugs/DB17724
    ApprovedInvestigational

    [L64098] Rusfertide is administered by subcutaneous injection and titrated to maintain hematocrit below 45%.

  4. Drug

    Prademagene zamikeracel

    go.drugbank.com/drugs/DB17895
    ApprovedInvestigational

    [L53013] It was granted an Orphan Drug designation by the EMA.[A273833] … [L53008] Prademagene zamikeracel was first approved by the FDA on April 29, 2025, for the treatment of recessive dystrophic epidermolysis bullosa (RDEB), a skin disorder associated with excessive blistering

  5. Drug

    Talbutal

    go.drugbank.com/drugs/DB00306
    ApprovedIllicit

    Talbutal, also called 5-allyl-5-sec-butylbarbituric acid, is a barbiturate with a short to intermediate duration of action. Talbutal is a schedule III drug in the U.S.

  6. Drug

    Selenic acid

    go.drugbank.com/drugs/DB11068
    Approved

    Selenic acid is an organic compound with the chemical formula H2SeO4. It may be found in over-the-counter daily dietary supplements as a source of DB11135, an essential trace mineral for human health.

  7. Drug

    Apremilast

    go.drugbank.com/drugs/DB05676
    ApprovedInvestigational

    [A181244,L7495] Initially approved in 2014, it is marketed by Celgene.

  8. Drug

    MN-246

    go.drugbank.com/drugs/DB05981
    Experimental

    MN-246 is a novel ß3-adrenergic receptor agonist developed for the treatment of urinary incontinence by MediciNova Inc.

  9. Drug

    Verpasep caltespen

    go.drugbank.com/drugs/DB04959
    Investigational

    It is being developed by StressGen Biotechnologies Corp. … E7 protein is involved in carcinogenesis of anal and cervical tumors, and represents a tumor antigen that may be specifically targeted by lymphocytes.

  10. Drug

    Albiglutide

    go.drugbank.com/drugs/DB09043
    ApprovedInvestigationalWithdrawn

    Albiglutide was approved on April 15, 2014 by the FDA. … It is marketed under the brands Eperzan and Tanzeum by GSK (GlaxoSmithKline). It is a dipeptidyl peptidase-4-resistant glucagon-like peptide-1 dimer fused to human albumin.